Marker Therapeutics (MRKR) Interest & Investment Income (2018 - 2026)
Marker Therapeutics (MRKR) reported Interest & Investment Income of $132889.0 for Q1 2026, down 18.22% year-over-year from $162489.0 in Q1 2025, and down 19.77% quarter-over-quarter from $165628.0 in Q4 2025.
Marker Therapeutics (MRKR) Interest & Investment Income (2018 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 9 years of Interest & Investment Income data on file, last reported at $132889.0 in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $132889.0, down 18.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $564606.0 (up 27.36% YoY), and the FY2025 annual result was $594206.0, up 35.97% from the prior year.
- Interest & Investment Income retreated to $132889.0 in Q1 2026 per MRKR's latest filing, from $165628.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $218085.0 in Q3 2023 and troughed at $3117.0 in Q1 2022.
- A 5-year average of $114783.9 and a median of $115388.0 in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income soared 12510.62% in 2022, then slumped 63.37% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at $109410.0 in 2022, then surged by 84.02% to $201339.0 in 2023, then tumbled by 63.37% to $73746.0 in 2024, then jumped by 124.59% to $165628.0 in 2025, then slipped by 19.77% to $132889.0 in 2026.
- Business Quant data shows MRKR's Interest & Investment Income at $132889.0 in Q1 2026, $165628.0 in Q4 2025, and $138064.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -14.79 Mn |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | 132,889.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132,889.00 |
| Dec 31, 2025 | 165,628.00 |
| Sep 30, 2025 | 138,064.00 |
| Jun 30, 2025 | 128,025.00 |
| Mar 31, 2025 | 162,489.00 |
| Dec 31, 2024 | 73,746.00 |
| Sep 30, 2024 | 91,681.00 |
| Jun 30, 2024 | 115,388.00 |
| Mar 31, 2024 | 156,195.00 |
| Dec 31, 2023 | 201,339.00 |
| Sep 30, 2023 | 218,085.00 |
| Jun 30, 2023 | 35,080.00 |
| Mar 31, 2023 | 84,654.00 |
| Dec 31, 2022 | 109,410.00 |
| Sep 30, 2022 | 99,750.00 |
| Jun 30, 2022 | 35,786.00 |
| Mar 31, 2022 | 3,117.00 |
| Dec 31, 2021 | 969.00 |
| Sep 30, 2021 | 791.00 |
| Jun 30, 2021 | 2,403.00 |